1039760-91-2
Chemical Structure
Rosolutamide
Synonym(s): ASC-JM17; ALZ-003
- CAS No.: 1039760-91-2
- Formula:C28H32O6
- Molecular Weight:464.55
IUPAC Name: (1E,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione
InChIKey: PJOSHEDKRPRCAE-QHKWOANTSA-N
SMILES: COC(C=C1/C=C/C(C(C(/C=C/C2=CC(OC)=C(C=C2)OC)=O)CC3CCC3)=O)=C(C=C1)OC
Biological Activity: Rosolutamide (ASC-JM17) is an orally active Nrf1/Nrf2 activator. Rosolutamide activates Hsf1 pathways, upregulates proteasome subunits and antioxidant enzymes, induces proteasome complex structural rearrangement, and enhances ubiquitin-proteasome system-mediated degradation. Rosolutamide reduces mutant androgen receptor and ataxin-3 aggregates, restores mitochondrial function, attenuates reactive oxygen species (ROS) levels, induces apoptosis and ferroptosis, and inhibits cancer cell growth. Rosolutamide can be used for the research of spinal and bulbar muscular atrophy, Huntington’s disease, and temozolomide-resistant glioblastoma[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rosolutamide | ≥98.0% | Rosolutamide (ASC-JM17) is an orally active Nrf1/Nrf2 activator. Rosolutamide activates Hsf1 pathways, upregulates proteasome subunits and antioxidant enzymes, induces proteasome complex structural rearrangement, and enhances ubiquitin-proteasome system-mediated degradation. Rosolutamide reduces mutant androgen receptor and ataxin-3 aggregates, restores mitochondrial function, attenuates reactive oxygen species (ROS) levels, induces apoptosis and ferroptosis, and inhibits cancer cell growth. Rosolutamide can be used for the research of spinal and bulbar muscular atrophy, Huntington’s disease, and temozolomide-resistant glioblastoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bott LC, et al. A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy. Hum Mol Genet. 2016;25(10):1979-1989. [Content Brief]
- [2]. Sedlacek J. Activation of the 26S Proteasome to Reduce Proteotoxic Stress and Improve the Efficacy of PROTACs. ACS Pharmacol Transl Sci. 2024 Dec 16;8(1):21-35. [Content Brief]
- [3]. Wu YL, et al. In Vitro Efficacy and Molecular Mechanism of Curcumin Analog in Pathological Regulation of Spinocerebellar Ataxia Type 3. Antioxidants (Basel). 2022;11(7):1389. Published 2022 Jul 18. [Content Brief]
- [4]. Osifová Z, et al. Diketo-Ketoenol Tautomers in Curcuminoids: Synthesis, Separation of Tautomers, and Kinetic and Structural Studies. J Org Chem. 2022 Aug 5;87(15):10309-10318. [Content Brief]
Keywords
